- Vitrolife's Q1 2025 sales amounted to SEK 842 million, representing a 1% increase in local currencies.
- EMEA showed strong regional growth of 8%, while APAC sales declined by 15%.
- EBITDA margin fell to 30.6% due to a SEK 13 million negative foreign exchange impact.
Vitrolife AB (publ) reported its Q1 2025 financial performance, showcasing varied regional outcomes. The company's sales reached SEK 842 million, marking a 1% growth in local currencies. However, growth remained flat in SEK terms. Excluding discontinued business, the growth rate stood at 3%.
Regional performance was mixed, with EMEA recording an 8% increase in sales, escalating to 14% after excluding discontinued operations. The Americas grew by 9%, offsetting a notable 15% sales decline in the APAC region.
By product category, disregarding discontinued business, Consumables experienced a 6% increase, Technologies saw a 5% decrease, and Genetics expanded by 4% in local currencies.
Vitrolife (VTRLY, Financial) achieved a slight improvement in gross margin from 57.1% to 57.4%. The company's EBITDA was SEK 257 million, down from SEK 272 million, translating to an EBITDA margin of 30.6%. This was primarily influenced by a negative foreign exchange impact of SEK 13 million.
Operating cash flow for the quarter stood at SEK 69 million, and net income was SEK 100 million. This resulted in earnings per share of SEK 0.74, compared to SEK 0.85 in the previous year.
